| 李昊,苏宗霞,崔冉.奥氮平片致神经阻滞剂恶性综合征 1例[J].安徽医药,2026,30(6):1270-1272. |
| 奥氮平片致神经阻滞剂恶性综合征 1例 |
| Olanzapine-induced neuroleptic malignant syndrome: a case report |
| |
| DOI：10.3969/j.issn.1009-6469.2026.06.041 |
| 中文关键词: 奥氮平 药物相关性副作用和不良反应 神经阻滞剂恶性综合征 精神分裂症 非典型抗精神病药物 |
| 英文关键词: Olanzapine Drug-related side effects and adverse reactions Neuroleptic malignant syndrome Schizophrenia Atypical antipsychotics |
| 基金项目:山东省药品不良反应监测中心委托项目( 2023SDADRKY44) |
|
| 摘要点击次数: 50 |
| 全文下载次数: 15 |
| 中文摘要: |
| 目的探讨奥氮平片引起神经阻滞剂恶性综合征(NMS)的发生特点，为精神科的临床安全用药提供参考。方法分析 2024年 3月淄博市精神卫生中心收治的 1例 70岁男性病人使用奥氮平片后出现 NMS的案例，评价 NMS与奥氮平片的相关性，并通过文献回顾的方法讨论分析奥氮平引起 NMS的特点及可能的发生机制。结果病人患有精神分裂症，口服给予奥氮平片治疗。药物治疗期间病人出现谵妄状态，高热，伴有大汗、血压升高、说话不清、全身震颤等症状。检查结果显示白细胞增多、肌酸激酶升高。诊断:奥氮平所致 NMS。停用奥氮平片，肌内注射东莨菪碱，静脉注射地西泮，静脉滴注头孢曲松钠、维生素 C、维生素 B6，结合物理降温等治疗方案，成功救治病人。结论 NMS为发生率低但危险性高的严重不良反应，临床应关注高龄病人使用奥氮平的不良反应风险，临床药师应加强用药监护。 |
| 英文摘要: |
| Objective To explore the characteristics of neuroleptic malignant syndrome (NMS) induced by olanzapine, and to providea reference for safe medication in psychiatric clinical practice.Methods A case of a 70-year-old male patient admitted to Zibo MentalHealth Center in March 2024 who developed NMS after receiving olanzapine was analyzed. The correlation between NMS and olanzap.ine was evaluated, and a literature review was conducted to discuss the characteristics and potential mechanism of NMS induced byolanzapine.Results The patient, diagnosed with schizophrenia, was treated with oral olanzapine. During medication, the patient devel.oped delirium, high fever, accompanied by profuse sweating, elevated blood pressure, dysarthria, and generalized tremor. Laboratory ex.amination showed leukocytosis and elevated creatine kinase. The diagnosis was NMS induced by olanzapine. The patient was success.fully treated with a combination of interventions including discontinuation of olanzapine, intramuscular scopolamine, intravenous diaze.pam, intravenous infusion of ceftriaxone sodium, vitamin C, and vitamin B6, along with physical cooling. Conclusions NMS isa severve adverse reaction with a low incidence but high risk. Clinicians should be vigilant about the risk of adverse reactions in elderlypatients receiving olanzapine, and clinical pharmacists should strengthen medication monitoring. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
